Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection

Archives of Internal Medicine

Volumn 157, Issue 16, 1997, Pages 1825-1831

  Jacobson, Mark A ^a,b,d   Liu, Rebecca Ching Chi ^a,c   Davies, Diane ^a,b   Cohen, P T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c Dixon Associates   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BACTERIAL INFECTION; FEMALE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEUTROPENIA; PRIORITY JOURNAL; RISK;

EID: 0030800770     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.16.1825     Document Type: Article

References (20)

1. Murphy MF, Metcalfe P, Waters AH, et al. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol. 1987;66:337-340.
2. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-340.
3. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever: a statement by the Infectious Diseases Society of America. J Infect Dis. 1991;161:381-396.
4. Chanock S. Evolving risk factors for infectious complications of cancer therapy. Hematol Oncol Clin North Am. 1993;7:771-793.
5. Moore RD, Keruly JC, Chaisson RE. Neutropenia and bacterial infection in acquired immunodeficiency syndrome. Arch Intern Med. 1995;155:1965-1970.
6. Shaunak S, Bartlett JA. Zidovudine-induced neutropenia: are we too cautious? Lancet. 1989;2:91-92.
7. Tumbarello M, Tacconelli E, Caponera S, Cauda R, Ortona L. The impact of bacteraemia on HIV infection: nine years experience in a large Italian university hospital. J Infect. 1995;31:123-131.
8. Farber BF, Lesser M, Kaplan MH, Woltmann J, Napolitano B, Armellino D. Clinical significance of neutropenia in patients with human immunodeficiency virus infection. Infect Control Hosp Epidemiol. 1991;12:429-434.
9. Whimbey E, Gold JWM, Polsky B, et al. Bacteremia and fungemia in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1986;104:511-514.
10. World Health Organization. International Classification of Diseases, Ninth Revision (ICD-9). Geneva, Switzerland: World Health Organization; 1977.
11. Arvesen JN. Jackknifing U-statistics. Ann Math Stat. 1969;40:2076-2100.
12. Terpstra FG, Al BJ, Roos MT, et al. Longitudinal study of leukocyte functions in homosexual men seroconverted for HIV: rapid and persistent loss of B cell function after HIV infection. Eur J Immunol. 1989;19:667-673.
13. Stanley HD, Charlebois E, Harb G, Jacobson MA. Central venous catheter infections in AIDS patients receiving treatment for cytomegalovirus disease. J Acquir Immune Defic Syndr. 1994;7:272-278.
14. Henry K, Thurn JR, Johnson S. Experience with central venous catheters in patients with AIDS. N Engl J Med. 1989;320:1494-1495.
15. Raviglione MC, Battan R, Pablos-Mendez A, et al. Infections associated with Hickman catheters in patients with acquired immunodeficiency syndrome. Am J Med. 1989;86:780-786.
16. Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med. 1992;327:1697-1703.
17. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med. 1995;333:845-851.
18. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992;327:1842-1848.
19. Kuritzkes D, Parenti D, Ward D, Rachlis A, Jacobson M, and the G-CSF 930101 Study Group. Filgrastim for prevention of severe neutropenia and associated clinical sequelae in HIV-infected patients: results of a 24-week, prospective, randomized, controlled trial. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections; January 26, 1997; Washington, DC.
20. Jacobson MA, Stanley HD, Heard SE. Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients. AIDS. 1992;6:515-517.